National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)     
Last Modified: 09/05/2008
Health Professional Version
Changes to This Summary (09/05/2008)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Purpose of This PDQ Summary 1

Added text 2 to state that some reference citations in the summary are accompanied by a level-of-evidence designation that is intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches.

Cellular Classification 3

Added Sevilla et al. as reference 8 4.

Disseminated Childhood B-cell Non-Hodgkin Lymphoma 5

Added text 6 to state that results from the pediatric international FAB/LMB study and BFM groups demonstrate that CNS disease at diagnosis is the strongest predictor of relapse for pediatric NHL, with the exception being lymphoblastic lymphoma (cited Salzburg et al. as reference 9).



Table of Links

1http://cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/HealthProfessio
nal/406.cdr#Section_406
2http://cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/HealthProfessio
nal/411.cdr#Section_411
3http://cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/HealthProfessio
nal/8.cdr#Section_8
4http://cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/HealthProfessio
nal/288.cdr#Section_288
5http://cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/HealthProfessio
nal/313.cdr#Section_313
6http://cancer.gov/cancertopics/pdq/treatment/child-non-hodgkins/HealthProfessio
nal/361.cdr#Section_361